Reuters logo
BRIEF-Novartis's Tasigna wins additional EU approval
November 20, 2017 / 6:18 AM / 25 days ago

BRIEF-Novartis's Tasigna wins additional EU approval

Nov 20 (Reuters) - Novartis AG

* Novartis drug Tasigna (nilotinib) secures eu approval for first and second-line treatment of ph+ cml-cp in children Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below